USP Zdrowie

uspzdrowie.pl

USP Health is a market leader in over the counter and over-the-counter (OTC) markets in Poland. The company's portfolio includes well-known brands. Apap, Ibuprom, Gripex, Verdin, Stoperan and Xenna.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMA TECH

CSL LIMITED ANNOUNCES TENDER OFFER TO ACQUIRE VIFOR PHARMA LTD

Vifor Pharma Group | December 15, 2021

news image

Global biotechnology leader CSL Limited and Vifor Pharma Ltd, a global specialty pharmaceutical company with leadership in iron deficiency, nephrology & cardio-renal therapies, announced that they have entered into a definitive agreement for CSL to acquire Vifor Pharma for an aggregate equity value for Vifor Pharma of US$ 11.7 / CHF 10.9 billion. CSL has offered to acquire Vifor Pharma in an all-cash tender offer of US$179.25 per share, payable in U.S. dollars.1 The offer assu...

Read More

PHARMA TECH

FUSION PHARMACEUTICALS ANNOUNCES PRESENTATION OF PRECLINICAL DATA SUPPORTING ITS FPI-1966 AND FPI-2059 TARGETED ALPHA THERAPIES

Fusion | October 23, 2021

news image

Fusion Pharmaceuticals a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of preclinical data that provide further support of its FPI-1966 and FPI-2059 targeted alpha therapies at the 34th Annual European Association of Nuclear Medicine Congress. These data reinforce the clinical dosing regimen of FPI-1966 and highlight the potential of FPI-2059 as an actinium-225 labelled precision medicine target...

Read More

BUSINESS INSIGHTS

KEDRION BIOPHARMA GROWS IN NORTH AMERICA AS IT COMPLETES ACQUISITION OF PROMETIC

Kedrion Biopharma | October 19, 2021

news image

Kedrion Biopharma, the rapidly growing international biopharmaceuticals company that produces and distributes plasma-derived treatments for rare diseases, has announced that it has completed the acquisition in North America of the Prometic life sciences business. Prometic, which has a team of 130 employees in Laval, Québec, has developed the first ever FDA-approved treatment for Congenital Plasminogen Deficiency. The new drug, called Ryplazim®, , has been approved for t...

Read More

PRACTICE MANAGEMENT

ROYALTY PHARMA ACQUIRES ROYALTY INTEREST IN ORLADEYO AND BCX9930 FROM BIOCRYST PHARMACEUTICALS

Royalty Pharma | December 08, 2020

news image

Royalty Pharma, BioCryst Pharmaceuticals, Inc. what's more, Athyrium Capital Management, LP today declared exchanges adding up to $325 million in financing for BioCryst, with $250 million accessible at shutting, to help the dispatch of ORLADEYO™ (berotralstat) in genetic angioedema (HAE) and the advancement of its oral Factor D inhibitor, BCX9930. Royalty Pharma will furnish BioCryst with a forthright money installment of $125 million and will get eminences of 8.75% on d...

Read More
news image

PHARMA TECH

CSL LIMITED ANNOUNCES TENDER OFFER TO ACQUIRE VIFOR PHARMA LTD

Vifor Pharma Group | December 15, 2021

Global biotechnology leader CSL Limited and Vifor Pharma Ltd, a global specialty pharmaceutical company with leadership in iron deficiency, nephrology & cardio-renal therapies, announced that they have entered into a definitive agreement for CSL to acquire Vifor Pharma for an aggregate equity value for Vifor Pharma of US$ 11.7 / CHF 10.9 billion. CSL has offered to acquire Vifor Pharma in an all-cash tender offer of US$179.25 per share, payable in U.S. dollars.1 The offer assu...

Read More
news image

PHARMA TECH

FUSION PHARMACEUTICALS ANNOUNCES PRESENTATION OF PRECLINICAL DATA SUPPORTING ITS FPI-1966 AND FPI-2059 TARGETED ALPHA THERAPIES

Fusion | October 23, 2021

Fusion Pharmaceuticals a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of preclinical data that provide further support of its FPI-1966 and FPI-2059 targeted alpha therapies at the 34th Annual European Association of Nuclear Medicine Congress. These data reinforce the clinical dosing regimen of FPI-1966 and highlight the potential of FPI-2059 as an actinium-225 labelled precision medicine target...

Read More
news image

BUSINESS INSIGHTS

KEDRION BIOPHARMA GROWS IN NORTH AMERICA AS IT COMPLETES ACQUISITION OF PROMETIC

Kedrion Biopharma | October 19, 2021

Kedrion Biopharma, the rapidly growing international biopharmaceuticals company that produces and distributes plasma-derived treatments for rare diseases, has announced that it has completed the acquisition in North America of the Prometic life sciences business. Prometic, which has a team of 130 employees in Laval, Québec, has developed the first ever FDA-approved treatment for Congenital Plasminogen Deficiency. The new drug, called Ryplazim®, , has been approved for t...

Read More
news image

PRACTICE MANAGEMENT

ROYALTY PHARMA ACQUIRES ROYALTY INTEREST IN ORLADEYO AND BCX9930 FROM BIOCRYST PHARMACEUTICALS

Royalty Pharma | December 08, 2020

Royalty Pharma, BioCryst Pharmaceuticals, Inc. what's more, Athyrium Capital Management, LP today declared exchanges adding up to $325 million in financing for BioCryst, with $250 million accessible at shutting, to help the dispatch of ORLADEYO™ (berotralstat) in genetic angioedema (HAE) and the advancement of its oral Factor D inhibitor, BCX9930. Royalty Pharma will furnish BioCryst with a forthright money installment of $125 million and will get eminences of 8.75% on d...

Read More